inhibition results in apoptosis of tumor cells whose lipids, especially phospholipids, were decreased by over 50%, suggesting involvement of phospholipids like sphingosine-1-phosphate (S1P) in AKR1B10's oncogenic function. Using a co-culture system, we found that co-culture of QSG-7701 (human hepatocyte) with HepG2 (hepatoma cell line) increases QSG-7701's proliferation, in which AKR1B10-S1P signaling plays a pivotal role. Consistent with previous findings, AKR1B10 mRNA and protein levels were higher in primary hepatocellular carcinoma (PHC) tissues than in peri-tumor tissues. Interestingly, the level of S1P was also higher in PHC tissues than in peri-tumor tissues. After analyzing the correlation between AKR1B10 mRNA expression in PHC tissues and the clinical data, we found that AKR1B10 mRNA expression was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) stage, and lymph node metastasis, but not with other clinicopathologic variables. A higher AKR1B10 mRNA expression level is related to a shorter DFS (disease free survival) and OS (overall survival), serving as an independent predictor of DFS and OS in PHC patients with surgical resection.
Primary hepatocellular carcinoma (PHC) is an extremely virulent form of tumor, causing 745,000 deaths in 2012, and is the second most common cause of cancer death in the world according to statistics gathered by GLOBOCAN 1 . Due to its late presentation, the prognosis of PHC is grim, with a median survival time of less than 2 years 2 and a 5 year-survival rate of 15% after diagnosis (http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-survival-rates). Thus seeking novel treatment methods and finding biomarkers for early diagnosis of PHC are beneficial to improving the survival rate of patients.
Aldo-keto reductase family 1 member B 10 (AKR1B10), also known as aldose reductase-like-1 (ARL-1), had been cloned from PHC 3 . Growing evidence has confirmed that AKR1B10 is associated with the development and progression of many cancers such as hepatocellular carcinoma [4] [5] [6] , smoking-related non-small-cell lung cancer 4, 7, 8 , esophageal adenocarcinoma 9 , gastric cancer 10 , breast cancer 11 , cervical cancer 12 , and pancreatic cancer 13 . Recently, a report implicated AKR1B10 in hepatocarcinogenes is via modulation of proliferation and apoptosis 5 . A previous study revealed that inhibition of AKR1B10 results in apoptosis of tumor cells, in which cellular lipids, especially phospholipids, were decreased by over 50% 14 . This important study prompts us to hypothesize that phospholipids are involved in AKR1B10's oncogenic function. As a bioactive phospholipid, sphingosine-1-phosphate (S1P) is involved in cancer progression including cell transformation/oncogenesis, cell survival/apoptosis, cell migration/metastasis, and tumor microenvironment neovascularization 15 . Therefore, we hypothesized that S1P plays a pivotal role in AKR1B10's oncogenic function. In this study, we found that co-culture of QSG-7701 (human hepatocyte) with HepG2 (hepatoma cell line) increases QSG-7701's proliferation, and that AKR1B10-S1P signaling is necessary for this increase in proliferation; up-regulation of AKR1B10 and S1P levels was also confirmed in PHC tissues.
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Increase in QSG-7701 cell proliferation by co-culture with HepG2 was caused by the difference in cellular AKR1B10 and not secreted AKR1B10 between two cell lines. Because AKR1B10 was reported to be involved in cell proliferation, we first investigated the difference in AKR1B10 expression between HepG2 and QSG-7701. Western Blotting revealed that AKR1B10 protein is highly expressed in HepG2 cells but non-detectable in QSG-7701 cells ( Fig. 2A) . Consistent with this, AKR1B10 activity was higher in HepG2 cell lysates than in QSG-7701 (Fig. 2B) . Also, consistent with a previous report that AKR1B10 could be secreted 18 , we observed by ELISA that the level of AKR1B10 was higher in the medium from cultured HepG2 than that from QSG-7701 (Fig. 2C) . The AKR1B10 activity was also higher in the medium from HepG2 than that from QSG-7701 (Fig. 2D) . As we observed, QSG-7701 cell proliferation was increased by conditional medium from HepG2 cells or when co-cultured with HepG2. Interestingly, this enhancement could not be observed by using conditional medium from HepG2 cells whose AKR1B10 was inhibited by AKR1B10-specific siRNA (Fig. 2E) . Efficiency of siRNA inhibition was confirmed by Western blotting (Fig. 2F) . Although down-regulation of AKR1B10 in HepG2 cells could ameliorate AKR1B10 secretion into the medium (Fig. 2G) , secreted AKR1B10 was not necessary for the increase in QSG-7701 cell proliferation by co-culture with HepG2, as this phenomenon was not blocked by AKR1B10 antibody (Fig. 2H) . These results confirm that the difference in cellular and not secreted AKR1B10 between the two cell lines plays a key role in the increase in QSG-7701 cell proliferation by co-culture with HepG2. S1P, the downstream signaling molecule of AKR1B10, plays a key role in the increase in QSG-7701 cell proliferation when co-cultured with HepG2. We observed that secreted S1P is higher in media from HepG2 cells than from QSG-7701 (Fig. 3A) . In addition, increased QSG-7701 cell proliferation by conditional medium from HepG2 cells could be inhibited by S1P antibody (Fig. 3B) . As expected, down-regulation of AKR1B10 in HepG2 cells could reduce S1P level in the medium (Fig. 3C) . As we predicted, knockdown of AKR1B10 inhibited cell growth in HepG2 cells but not in QSG-7701, and adding S1P could reverse this inhibition in HepG2 cells (Fig. 4 ).
Up-regulation of AKR1B10 and S1P in PHC. Our data suggest that signaling by AKR1B10-S1P is involved in the increase in QSG-7701 cell proliferation by co-culture with HepG2 cells. To understand whether this observation is clinically significant, we investigated AKR1B10 gene expression in PHC tissues, and observed that mRNA level of AKR1B10 was higher in human PHC tissues than in peri-tumor tissues (99 in 144, 68.8%) (Fig. 5A ). Secondly, IHC results ( Fig. 5C) confirmed that the protein level of AKR1B10 was higher in PHC tissues than peri-tumor tissues. Consistent with this, the positive rate of detection for AKR1B10 was higher in PHC tissues (83.0%, 39 in 47) than in peri-tumor tissues (25.5%, 12 in 47) (p < 0.0001). Thirdly, Western blotting confirmed the above results (Fig. 5B ). In addition, using tissues from 20 patients, S1P level as measured by competitive ELISA was up to 18.51 ± 3.78 μM (mean ± SD) in PHC homogenate, which is significantly higher than that observed in peri-tumor tissues homogenate (2.92 ± 0.74 μM, p < 0.05).
AKR1B10 expression level in PHC tissues and its clinical significance.
A score of 0.503 of relative AKR1B10 mRNA in cancer tissue was determined from an ROC curve obtained by MedCalc analysis based on our recent report 19 and identified as the cut-off with the best sensitivity and the maximum specificity to predict the status of survival. After analyzing the correlation of AKR1B10 mRNA expression in PHC tissues and the clinical data (Table 1) , we found that AKR1B10 mRNA expression was correlated with serum alpha-fetoprotein (AFP) level, tumor-node-metastasis (TNM) stage, and lymph node metastasis, but not with other clinicopathologic variables, such as age and gender. The data from Kaplan-Meier survival analysis revealed that a higher AKR1B10 mRNA expression level was related to a shorter DFS and OS (Fig. 6 ). Univariate analysis (Table 2) confirmed that the mean DFS in PHC patients with high AKR1B10 expression was 29.29 months compared with 47.04 months in PHC patients with low AKR1B10 expression, and the mean OS in the high AKR1B10 expression group was 34.80 months compared with 51.18 months in the low AKR1B10 expression cohort. In addition to AKR1B10 expression level, some clinical parameters like gender, tumor size, tumor number, TNM stage, and portal vein tumor thrombus (PVTT) were associated with DFS. The association between recurrence along with above DFS-associated clinical parameters and OS was also identified. The Cox multivariate proportional hazard model was utilized to determine whether or not some factors including AKR1B10 mRNA expression could be independent predictors of the DFS and OS of PHC patients who underwent surgical resection. Data showed that tumor size (≥ 5 cm), PVTT (yes) and AKR1B10 mRNA expression level (high) were independent predictors for DFS and OS (Table 3 ). In addition, recurrence was related to OS but not to DFS, and recurrence (yes) could be used as an independent predictor for OS (Table 3) .
Discussion
AKR1B10 is cloned from PHC 3 , and its up-regulation in PHC has been confirmed in some studies 3, 6 . In agreement with these studies, this study showed that AKR1B10 mRNA level was higher in human PHC tissues than in peri-tumor tissues (99 in 144, 68.8%) and the protein level of AKR1B10 was also higher in PHC tissues than in peri-tumor tissues. Also, the IHC positive rate of AKR1B10 is 83.0% in PHC tissues and 25.5% in peri-tumor tissues.
Consistent with a recent report that AKR1B10 is involved in hepatocarcinogenesis by modulating cell proliferation and apoptosis 5 , we found that co-culture of QSG-7701 (human hepatocyte) with HepG2 (hepatoma cell line) increases QSG-7701's proliferation, and this increase is modulated by a higher level of cellular AKR1B10 in HepG2 than in QSG-7701. AKR1B10 can be secreted outside 18 , but secreted AKR1B10 was not necessary for the increase in QSG-7701 cell proliferation by co-culture with HepG2 because this phenomenon was not blocked by AKR1B10 antibody. The increase in QSG-7701 cell proliferation can be observed when cultured with conditional medium from HepG2 cells, but cannot be observed if AKR1B10 in HepG2 cells was downregulated by siRNA. Thus an indirect effect by cellular AKR1B10 and not secreted AKR1B10 from HepG2 cells accounts for the increase in QSG-7701 cell proliferation by co-culture with HepG2. We speculated that S1P is the potential molecule downstream of AKR1B10 that may be directly mediating this increase in QSG-7701 cell proliferation. It is well known that secreted S1P is a bioactive phospholipid involved in cell proliferation 15 . Supporting our hypothesis, we found that secreted S1P is much higher in HepG2 than in QSG-7701, and S1P antibody could block the increase in QSG-7701 cell proliferation when cultured with conditioned medium from HepG2, and down-regulation of AKR1B10 reduced secreted S1P from HepG2. These data, together with a previous report that AKR1B10 inhibition results in apoptosis of tumor cells, in which the level of cellular phospholipids was decreased significantly 14 , prompted us to consider S1P as the potential molecule downstream of AKR1B10 that is involved in AKR1B10's oncogenic function. It is well known that AKR1B10 knockdown inhibits proliferation of cancer cells. To better understand signaling by AKR1B10 and S1P, we added S1P to these two cell lines in which AKR1B10 was knocked down to test if exogenous S1P could rescue this inhibition of cell proliferation. As we expected, AKR1B10 knockdown inhibited proliferation of HepG2 cells but not of QSG-7701. This may be because there is more AKR1B10 protein in HepG2 than in QSG-7701, and adding S1P could rescue the inhibition in proliferation of HepG2 cells (Fig. 4) . This hypothesis was also confirmed by the observation that AKR1B10 and S1P levels were much higher in PHC tissues than in peri-tumor tissues. In summary, we found that AKR1B10 is involved in cell proliferation of liver cancer through S1P. It is reported that AKR1B10 is involved in hepatocarcinogenesis via modulation of proliferation and cell apoptosis primarily through the synthesis of fatty acid, which is a substrate for sphingolipid metabolism pathway. Besides S1P, which is one of the most important signaling molecules in sphingolipid pathway, other upstream and downstream molecules of S1P and related enzymes in this pathway are also possibly implicated in this process. The association between AKR1B10 mRNA expression level and unfavorable prognosis was demonstrated in this study; however, inconsistent result was obtained in the previous studies analyzing AKR1B10 protein expression level. Therefore, 11 paired tissues from hepatocellular carcinoma were obtained to determine AKR1B10 mRNA and protein expression levels side by side (data not shown), and we found that AKR1B10 mRNA and protein expression levels are not always consistent in a same patient. The significant correlation between AKR1B10 mRNA and protein expression in hepatocellular carcinoma was not observed (p = 0.284), and thus, post-transcription mechanism might be involved in the role of AKR1B10 in hepatocarcenogenesis.
AKR1B10 is as a potential tumor marker 20 in non-small-cell lung cancer 21 and breast cancer 11 . AKR1B10 cloned from PHC has a potential to become a diagnostic and prognostic biomarker for PHC, and indeed, it was confirmed to be a marker for differentiation and proliferation of PHC 6 , an independent risk factor for PHC in chronic hepatitis C patients 22 , and a potential promising biomarker to differentiate PHCs from benign hepatic lesions 5 . Tissue micro-array data from two groups (one has 168 PHC patients and another one has 255 PHC patients) and further clinic-pathological data analysis revealed that a high AKR1B10 protein expression level reflects a less aggressive tumor behavior 16 and thus might be a favorable prognosis marker in PHC patients who underwent curative hepatectomy 17 . Given that protein expression is not always consistent with mRNA expression, we analyzed the correlation between AKR1B10 mRNA expression level and the clinical data from 144 cases of PHC. In line with a previous result of a proportional correlation between AKR1B10 expression level and serum AFP 22 , we observed that AKR1B10 mRNA expression level associated with serum AFP. We further confirmed that the mRNA expression level of AKR1B10 correlated with TNM stage and lymph node metastasis, and that a high AKR1B10 mRNA expression level was related to a shorter DFS and OS. Thus AKR1B10 mRNA expression level is an independent predictor on DFS and OS of PHC patients who underwent surgical resection. All these data are contradictory to a recent report that high AKR1B10 protein expression level might be useful as a marker of a favorable prognosis in patients with hepatocellular carcinoma after curative hepatectomy 17 . Different results might be caused by differences in methodology or cohort of samples.
In summary, co-culture of QSG-7701 (human hepatocyte) with HepG2 (hepatoma cell line) increased QSG-7701's proliferation, and this increase in proliferation is mediated by AKR1B10-S1P signaling. AKR1B10 and S1P expression levels were higher in PHC tissues than in peri-tumor tissues. AKR1B10 mRNA level correlated with serum AFP level, TNM stage, and lymph node metastasis. A higher AKR1B10 mRNA expression is related to shorter DFS and OS, and AKR1B10 mRNA high expression is an independent predictor in PHC patients with surgical resection. Additionally, AKR1B10-S1P is a potential therapeutic target in PHC. Table 3 . Cox multivariate proportional hazard model of independent predictors on disease-free and overall survival. CI, confidence interval; TNM, tumor-node-metastasis; PVTT, portal vein tumor thrombus.
humidified atmosphere at 37 °C. For some experiments, HepG2 and QSG-7701 were co-cultured in Corning Transwell plates (Sigma, St. Louis, MO), in which QSG-7701 cells were grown in the lower compartment and HepG2 cells were grown in the upper compartment. These two compartments were separated by a polycarbonate membrane with 0.4 μm pore size. AKR1B10 Antibody (sc-54255) was from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA) or from ABCAM (ab57547). AKR1B10 siRNA (sc-72342) and β -Actin Antibody (sc-130301) were also purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). The RNeasy mini kit was bought from Qiagen (Santa Clarita, CA, USA), and the iScript cDNA synthesis kit was from Bio-Rad Laboratories, Inc (Hercules, CA, USA). S1P competitive ELISA kit was purchased from Echelon Biosciences. Lipofectamine 2000 was from Invitrogen Corp (Carlsbad, CA, USA). Other unlisted chemicals were purchased from Sigma-Aldrich Co. LLC.
Cell growth assay. The number of viable cells was counted by hemacytometer using 0.4% Trypan Blue Solution (15250-061, Thermo Fisher Scientific Inc.) or determined by an in vitro toxicology assay kit (MTT-based; Sigma, St. Louis, MO, USA) as described in our previous study 23 .
SDS-polyacrylamide gel electrophoresis and Western blotting.
To obtain cell lysates, HepG2 or QSG-7701 cells were lysed in lysis buffer, and tissue samples were homogenized. These lysates were then analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting analysis as described previously 24 .
AKR1B10 activity Assay. Cell lysate, tissue homogenate, or medium were subjected to AKR1B10 enzyme activity assays using DL-glyceraldehyde as a substrate. AKR1B10 activity was expressed as oxidized NADPH (nmol)/protein (mg)/h for cell lysate and tissue homogenate or oxidized NADPH (nmol)/medium(ml)/h for medium as described previously 18 .
Sandwich ELISA. AKR1B10 in culture medium was quantified using Sandwich ELISA as described by Luo D et al.
18
.
Blocking studies. For studies in which antibodies were used to block S1P or AKR1B10, QSG-7701 cells were treated with conditional medium from HepG2 cells in the absence or presence of S1P or AKR1B10 antibody (2.5-10 μg/ml) for 24 h. The isoform-matched control antibody was used. After the incubation, the number of viable cells was quantified as above.
Scientific RepoRts | 6:22746 | DOI: 10.1038/srep22746 survival probability was calculated by Kaplan-Meier method, and survival curves between two groups were compared using the log-rank test. Independent predictors related to DFS were analyzed by using Stepwise Cox proportional hazard models. A value of P < 0.05 was considered as statistically significant.
